与癌症相关的 RNA 甲基化改变的发现有望将其用作癌症诊断、预后和预测的潜在生物标志物。人们发现 RNA 甲基化会影响肿瘤的免疫微环境，但甲基化相关基因 (MRG) 在肿瘤微环境中的具体作用仍不清楚，特别是在乳腺癌 (BC) 中，乳腺癌是全球女性中最常见的癌症。在这项研究中，我们从 TCGA 和 GEO 数据库中获取了数据，以研究 BC 基因组和转录域中 MRG 的表达模式。通过分析数据，我们确定了两种不同的遗传分组，它们与患者的临床病理特征、预后、TME 细胞浸润程度以及 MRG 的其他异常相关。随后，开发了 MRG 模型来预测总生存期 (OS)，并在 BC 患者中评估其准确性。此外，还创建了高精度列线图以增强 MRG 模型的实际可用性。在低风险组中，我们观察到较低的 TBM 值和较高的 TIDE 分数。我们进一步探讨了 MRG 如何影响患者的预后、临床显着特征、治疗反应和 TME。这些风险特征有可能改善 BC 患者的治疗策略，并可应用于未来的临床环境。此外，它们还可以用于确定这些患者的预后和生物学特征。

The discovery of RNA methylation alterations associated with cancer holds promise for their utilization as potential biomarkers in cancer diagnosis, prognosis, and prediction. RNA methylation has been found to impact the immunological microenvironment of tumors, but the specific role of methylation-related genes (MRGs), particularly in breast cancer (BC), the most common cancer among women globally, within the tumor microenvironment remains unknown. In this study, we obtained data from TCGA and GEO databases to investigate the expression patterns of MRGs in both genomic and transcriptional domains in BC. By analyzing the data, we identified two distinct genetic groupings that were correlated with clinicopathological characteristics, prognosis, degree of TME cell infiltration, and other abnormalities in MRGs among patients. Subsequently, an MRG model was developed to predict overall survival (OS) and its accuracy was evaluated in BC patients. Additionally, a highly precise nomogram was created to enhance the practical usability of the MRG model. In low-risk groups, we observed lower TBM values and higher TIDE scores. We further explored how MRGs influence a patient's prognosis, clinically significant characteristics, response to therapy, and the TME. These risk signatures have the potential to improve treatment strategies for BC patients and could be applied in future clinical settings. Moreover, they may also be utilized to determine prognosis and biological features in these patients.